BioPharma Resources

Drug Trial Radar · NCT05715840

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase Ш Clinical Study to Evaluate the Efficacy and Safety of First-line Treatment With SG001 Plus Chemotherapy±Bevacizumab Versus Placebo Plus Chemotherapy±Bevacizumab for PD-L1 Positive (CPS≥1) Women With Recurrent, or Metastatic Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 368 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

368

Planned (sponsor's estimate)

Start

Jan 31, 2023

Primary completion

Jul 31, 2024

Study completion May 31, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomised, double-blind, placebo-controlled, multicentre phase 3 clinical study to evaluate the efficacy and safety of SG001 plus chemotherapy±bevacizumab versus placebo plus chemotherapy±bevacizumab, as first-line treatment, in patients with PD-L1 positive (CPS≥1), Recurrent or Metastatic Cervical Cancer. The study contains a Safety Lead-in Phase in which the safety and tolerability of SG001+Chemotherapy±Bevacizumab will be assessed prior to the Phase 3 portion of the study.

Conditions

  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Interventions

  • SG001 injectionDrug

    360 mg,Q3W,IV infusion

  • PaclitaxelDrug

    175 mg/m\^2,Q3W,IV infusion

  • CisplatinDrug

    50 mg/m\^2,Q3W,IV infusion

  • CarboplatinDrug

    AUC=5,Q3W,IV infusion

  • Bevacizumab injectionDrug

    15 mg/kg,Q3W,IV infusion

  • SG001 placeboDrug

    Q3W,IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead-inTime frame: Up to 42 days after the last patient of the lead-in phase
  2. PFS per RECIST 1.1Time frame: Up to approximately 3 years
  3. Overall survival (OS)Time frame: Up to approximately 3 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.